SAG
MREO

SageView Advisory Group’s Mereo BioPharma MREO Stock Holding History

SageView Advisory Group’s Portfolio MREO Stock Details MREO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$68 Buy
+161
New +$306 ﹤0.01% 2557

Other funds holding MREO

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

SageView Advisory Group's MREO Position: Q4 2025 in Review

SageView Advisory Group opened a new position in Mereo BioPharma (MREO) in Q4 2025: 161 shares worth $68. The stake represents ﹤0.01% of the portfolio and ranks #2557 among its holdings.

70 funds tracked by Wall St. Rank hold MREO as of Q4 2025.

  • SageView Advisory Group held 161 shares of Mereo BioPharma worth $68 as of Q4 2025.
  • Mereo BioPharma was a new SageView Advisory Group position in Q4 2025.
  • Mereo BioPharma made up ﹤0.01% of SageView Advisory Group's portfolio in Q4 2025, its #2557 holding.
  • 70 funds tracked by Wall St. Rank held Mereo BioPharma as of Q4 2025.

Based on SageView Advisory Group's 13F filing for Q4 2025, filed 17 Feb 2026.